Clinical parameter
|
Diabetic subjects
|
Controls
|
P(ANOVA)
|
---|
|
PCO (n = 64)
|
Non-PCO (n = 41)
|
PCO (n = 22)
|
Non-PCO (n = 38)
| |
---|
Fasting glucose (mg/dl)
|
123.8 ± 36.28
|
115.55 ± 32.0
|
92.14 ± 12.7
|
85.71 ± 14.6
|
0.000
|
Total cholesterol (mg/dl)
|
189.4 ± 40.9
|
199.8 ± 57.0
|
183.27 ± 37.6
|
183.87 ± 41.3
|
0.375
|
Triglycerides (mg/dl)
|
194.4 ± 69.9
|
192.4 ± 67.8
|
182.27 ± 52.1
|
187.65 ± 80.2
|
0.895
|
HDL cholesterol (mg/dl)
|
42.0 ± 6.6
|
43.3 ± 8.8
|
44.00 ± 11.0
|
43.99 ± 7.6
|
0.593
|
LDL cholesterol (mg/dl)
|
127.5 ± 55.2
|
131.1 ± 71.9
|
97.74 ± 40.7
|
105.76 ± 40.0
|
0.033
|
VLDL cholesterol (mg/dl)
|
38.8 ± 13.9
|
38.4 ± 13.5
|
36.45+10.4
|
37.53+16.0
|
0.895
|
LH (IU/L)
|
7.51+6.65
|
3.42 +2.21a
|
7.93 ± 9.52
|
2.77 ± 2.17b
|
0.000
|
FSH (IU/L)
|
5.82+2.80
|
7.23+4.86
|
5.50 ± 2.3
|
5.11 ± 2.9
|
0.039
|
LH/FSH ratio
|
1.31 ± 0.78
|
0.55 ± 0.26a
|
1.3 ± 0.85
|
0.5 ± 0.26b
|
0.000
|
Testosterone (ng/ml)
|
37.4 ± 23.0
|
16.9 ± 7.3a
|
39.6 ± 13.3
|
18.8 ± 7.5b
|
0.000
|
Androstendione (ng/ml)
|
2.40 ± 1.9
|
1.04 ± 0.36a
|
2.10 ± 0.6
|
1.21 ± 0.40b
|
0.000
|
- * Mean ± SD
- a: P < 0.05, in the subject group, b: P < 0.05, in control group